Adult-Onset Type 1 Diabetes Linked to Elevated Cardiovascular Risk and Mortality

A groundbreaking study recently published in the European Heart Journal has shed critical light on the health consequences faced by individuals who develop type 1 diabetes in adulthood. Contrary to long-held assumptions that adult-onset type 1 diabetes might present a milder clinical picture or improved prognosis compared to childhood-onset disease, this new research reveals a stark reality: the risk of cardiovascular disease (CVD) and mortality is significantly elevated in adults diagnosed with type 1 diabetes, and importantly, those diagnosed later in life fare no better than those diagnosed at younger ages. This large-scale observational study, conducted by a team at the prestigious Karolinska Institutet in Sweden, delves deeply into the factors that worsen outcomes, emphasizing the complex interplay between lifestyle choices, metabolic control, and disease management strategies in this population.

Historically referred to as "juvenile diabetes," type 1 diabetes is an autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas, leading to lifelong dependence on exogenous insulin. However, emerging epidemiological evidence has long suggested that the disease is not confined to childhood. Adults can develop type 1 diabetes at any age, but scientific knowledge about adult-onset type 1 diabetes remains scant, especially regarding long-term outcomes and risk profiles. Recognizing this gap, the Karolinska research group embarked on an extensive registry-based investigation, spanning two decades (2001-2020), to ascertain the cardiovascular risks and mortality rates associated with adult-onset type 1 diabetes, with a particular focus on individuals diagnosed after the age of 40.

The cohort involved in this study was impressively large, including over 10,000 adults newly diagnosed with type 1 diabetes, matched against more than half a million controls from the general population. This substantial sample size allowed the researchers to robustly compare outcomes and identify patterns that might otherwise be obscured in smaller or shorter-term studies. Their analyses revealed that adults diagnosed with type 1 diabetes face a markedly increased incidence of major cardiovascular events, including myocardial infarction, stroke, and peripheral arterial disease, as well as a higher all-cause mortality rate encompassing deaths from cancer and infections.

At the heart of these adverse outcomes lie key modifiable risk factors: tobacco smoking, obesity, and suboptimal glucose control. The researchers determined that these factors synergistically amplify the risk of cardiovascular complications and mortality in adult-onset type 1 diabetes. Notably, individuals diagnosed later in life were found less likely to utilize advanced assistive technologies such as insulin pumps, which have been previously demonstrated to facilitate tighter glycemic control and reduce the risk of complications. The underuse of such technologies in older adults may contribute to their elevated risk profile, pointing to the need for tailored therapeutic approaches that address barriers to technology adoption in this demographic.

First author Dr. Yuxia Wei, a postdoctoral fellow at the Institute of Environmental Medicine, highlighted the persistence of these risk factors and their implications: “We observed that smoking, overweight or obesity, and poor glucose control were the main drivers of the poor prognosis among adults with type 1 diabetes. Furthermore, the limited use of insulin pumps in this group underscores a potential area for intervention.” The findings challenge the misconception that adult-onset type 1 diabetes is inherently less dangerous or more easily manageable compared to childhood-onset disease.

Senior author Sofia Carlsson, an associate professor at Karolinska Institutet, emphasized the clinical importance of these results. She underscored that “the seriousness of type 1 diabetes should be acknowledged regardless of the age at diagnosis.” Professor Carlsson further stressed the potential for improving outcomes through targeted prevention strategies, stating that “by focusing on smoking cessation, obesity reduction, and enhancing glucose control, especially in older adults, we can significantly improve prognosis and reduce cardiovascular risk.”

Understanding why adult-onset type 1 diabetes carries such risks requires an examination of the pathophysiological mechanisms involved. Type 1 diabetes leads to chronic hyperglycemia, which triggers a cascade of metabolic disturbances, endothelial dysfunction, and inflammation—hallmarks of atherosclerosis and subsequent cardiovascular disease. When compounded by lifestyle factors such as tobacco use and excess adiposity, the vascular system endures heightened oxidative stress and structural damage, accelerating the progression of cardiovascular complications. Insufficient glycemic control exacerbates these effects by promoting advanced glycation end-products and impairing vasodilatory responses.

Moreover, the study’s revelation that adults diagnosed later in life are less likely to use insulin pump therapy raises questions about clinical practice and patient engagement. Insulin pumps offer continuous subcutaneous insulin infusion that more closely mimics physiological insulin release, improving glycemic stability and reducing hypoglycemia. Barriers such as perceived complexity, patient age, comorbidities, and healthcare system limitations may reduce adoption rates among older adults. Addressing these barriers is essential to optimizing treatment paradigms and mitigating the elevated cardiovascular risks observed.

This expansive registry study also calls attention to broader implications for public health and diabetes management guidelines. The pronounced mortality risk from not only cardiovascular disease but also cancer and infections highlights the multisystem impact of adult-onset type 1 diabetes. It underscores the need for comprehensive care models that integrate aggressive cardiovascular risk reduction, vigilant cancer screening, and infection prevention strategies alongside meticulous glycemic management.

Looking forward, the Karolinska team intends to deepen their investigation into adult-onset type 1 diabetes by exploring additional risk factors implicated in disease progression and complications. They aim to elucidate the interplay between microvascular complications—such as nephropathy, retinopathy, and neuropathy—and cardiovascular outcomes. Furthermore, evaluating the optimal utilization of technological advancements including insulin pumps, continuous glucose monitoring, and emerging therapeutics in adult populations remains a priority, as these tools hold promise for refining treatment and improving quality of life.

The considerable scope and rigor of this study, supported by funding from the Swedish Research Council and the Swedish Diabetes Foundation, provide compelling evidence that challenges prevailing narratives about adult-onset type 1 diabetes. The absence of reported conflicts of interest reinforces the credibility and impartiality of the findings. Collectively, the research advocates for an urgent recalibration of clinical awareness and intervention efforts targeted at adults receiving a type 1 diabetes diagnosis, emphasizing that age at onset does not mitigate the need for aggressive risk factor modification and advanced disease management.

In conclusion, this landmark study adds a crucial dimension to our understanding of type 1 diabetes across the lifespan. It dispels assumptions that adult-onset forms of the disease are inherently less dangerous and spotlights the vital importance of addressing smoking, obesity, and glycemic control. It also highlights the necessity for greater adoption of insulin pump technology and other advanced therapies to optimize outcomes. As the global burden of diabetes continues to surge, the insights offered by this research pave the way for refined strategies to reduce morbidity and mortality among adults grappling with this challenging autoimmune condition.

News Publication Date: 14-May-2025

Web References:
https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehaf304

References:
Wei Y, Andersson T, Tuomi T, Nyström T, Carlsson S. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. European Heart Journal. 2025 May 14. doi: 10.1093/eurheartj/ehaf304.